A computer model for the measurement of compliance using a dual tracer technique

British Journal of Clinical Pharmacology

Volumn 43, Issue 3, 1997, Pages 283-290

  Shine, D ^a   McDonald, J ^a  

^a LINCOLN MEDICAL AND MENTAL HEALTH CENTER   (United States)

Author keywords

compliance; digitoxin; mathematical modeling; phenobarbitone

Indexed keywords

DIGITOXIN; PHENOBARBITAL; TRACER;

ARTICLE; COMPUTER; DRUG ELIMINATION; DRUG HALF LIFE; PATIENT COMPLIANCE; PRIORITY JOURNAL; STATISTICS; THEORETICAL STUDY;

EID: 0031059372     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.00544.x     Document Type: Article

References (16)

1. Gordis L. General concepts for use of markers in clinical trials. Controlled Clinic Trials 1984; 5(4Suppl): 481-487.
2. Bond WS and Hussar DA. Detection methods and strategies for improving medication compliance. Am J Hosp Pharm 1991; 48: 1978-1987.
3. Roth HP. Accuracy of doctors estimates and patients statements on adherence to a drug regimen. Clin Pharmacol Ther 1978; 23: 361-370.
4. Rudd P. In search of the gold standard for compliance measurement. Arch Intern Med 1979; 139: 627-628.
5. Gordis L. Conceptual and methodologic problems in measuring patient compliance in medical practice and clinical trials, eds. Cramer JA, Spilker B. Raven Press, New York 1991; pp 23-45.
6. Insull W. Evaluation and recommendations for adherence marker development by working groups of the workshop. Controlled Clinic Trials 1984; 5: 579-583.
7. Roberts SB, Morrow FD, Evans WJ, et al. Use of p-aminobenzoic acid to monitor compliance with prescribed dietary regimens during metabolic balance studies in man. Am J Clin Nutr 1990; 51: 485-488.
8. Wolff K, Hay A, Raistrick D, Calvert R, Feely M. Measuring compliance in methadone maintenance patients: use of a pharmacologic indicator to 'estimate' methadone plasma levels. Clin Pharmacol Ther 1991; 50: 199-207.
9. Maenpaa H, Javela K, Pikkarainen J, Malkonen M, Heinonen OP, Manninen V. Minimal doses of digoxin: a new marker for compliance to medication. Eur Heart J 1987; 8(Suppl I): 31-37.
10. Good W, Leeson LJ, Zak SL, Wagner WE, Meeker JB, Arnold JD. Oros controlled-release formulations of metoprolol: an approach to the development of a system for once-daily administration. Br J Clin Pharmacol 1985; 19: 231s-238s.
11. Penn ND, Peaker S, Griffiths AP, Feely M, Tindall H. Use of a pharmacological indicator to monitor compliance with thyroxine. Eur J Clin Pharmacol 1988; 35: 327-329.
12. Feely M, Kumar S, Peaker S, Chrystyn H, Rice P, Pullar T. Use of a pharmacokinetic model to predict steady state phenobarbitone levels. Eur J Clin Pharmacol 1989; 36(suppl): a182.
13. Feely M, Cooke J, Price D. Low dose phenobarbitone as in indicator of compliance with drug therapy. Br J Clin Pharmacol 1987; 24: 77-83.
14. Pullar T, Birtwell AJ, Wiles PG, Hay A, Feely M. Use of a pharmacologic indicator to compare compliance with tablets prescribed to be taken once, twice, or three times daily. Clin Pharmacol Ther 1987; 44: 540-545.
15. Hardy E, Kumar S, Peaker S, Feely M, Pullar T. A comparison of short half-life marker (low-dose isoniazid), a long half-life pharmacological indicator (low-dose phenobarbitone), and measurements of a controlled release 'therapeutic drug' (metoprolol, motoros) in reflecting incomplete compliance by volunteers. Br J Clin Pharmacol 1990; 30: 437-441.
16. Pullar T, Kumar S, Chrystyn H, Rice P, Peaker S, Feely M. The prediction of steady state plasma phenobarbitone concentrations (following low dose phenobarbitone) to refine use as an indicator of compliance. Br J Clin Pharmacol 1991; 32: 329-333.